Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

Spoiler alert: sentiment expressed is caution rather than extreme optimism!

I reference here a wonderful post #91106, by the intrepid sclimmuno, in which he lists details about two drugs already approved, Dalbavancin, and Ortanavancin. Both are Brilacidin competitors, as you know, for skin infections. The first drug requires 2 iv doses, and the second one, only one IV dose. as compared to multi day Vancomycin treatment. Brilacidin did very well against Daptomycin, and offers the benefit of a one time dose. But one of the drugs referenced is also a single dose. Will a large company bide its time and let brilacidin prove it can beat those other already approved drugs? Or will they buy in ahead of time on the chance that Brilacidin will be better? There is no proof yet that Brilacidin can beat those other drugs that I know of- perhaps others have more info.

And Kevetrin:again,a couple of years away from proving its benefit in head to head trials. Human dosing still being worked out. IF the later cohorts show positive results there will be dramatic interest in this stock- but that has not been demonstrated in actual patients yet. This is a company that will not be shy to trumpet success- note PR released previously about a single patient, the one with ovarian CA. More PR from later cohorts will be needed to prove K really something special, and then of course, will need actual trial data to prove benefits.

In other words planning to retire at a share price of $30 or higher for CTIX is rather optimistic- at this point in time.